Full-Suite Services for the Psychedelic Industry
Psilonautica is expanding its reach, bringing together a diverse network of contractors to offer a full spectrum of psychedelic solutions.
Service Areas
Science
- Literature Reviews
- Research Support
- Clinical Trial Protocol Design
- Collaborations with Leading Psychedelic Institutions and CROs
- Real World Evidence Study Design
- IRB Applications and Research Ethics Review
Legal
- Legal Documentation
- Regulatory Pathway Development
- Licence Obtention
- Regulatory Briefing Packages
- Import and Export of Scheduled Compounds
Operations
- Retreat and Clinic Operations
- Interdisciplinary Collaboration Facilitation
- Human Resources, Hiring and Auditing Staff
- Crisis Management and Avoidance
- Psychedelic Education Curriculum Development
Communications
- Social Media Implementation and Strategy
- Public Relations and Press Liaison
- Website Development, Search Engine Optimisation and UI/UX Strategies
- Event Organisation and Execution
- Media Training
Finance
- Business Development Services
- Funding Advise (Seed through to Pre IPO)
- Investor Relations
- Capital introduction
- Tax and Accountancy
Ethics
- Ethical Protocol Review
- Informed Consent Design
- Independent Ethics Audits
- IRB Review
Science
- Literature Reviews
- Research Support
- Clinical Trial Protocol Design
- Collaborations with Leading Psychedelic Institutions and CROs
- Real World Evidence Study Design
- IRB Applications and Research Ethics Review
Legal
- Legal Documentation
- Regulatory Pathway Development
- Licence Obtention
- Regulatory Briefing Packages
- Import and Export of Scheduled Compounds
Operations
- Retreat and Clinic Operations
- Interdisciplinary Collaboration Facilitation
- Human Resources, Hiring and Auditing Staff
- Crisis Management and Avoidance
- Psychedelic Education Curriculum Development
Communications
- Social Media Implementation and Strategy
- Public Relations and Press Liaison
- Website Development, Search Engine Optimisation and UI/UX Strategies
- Event organisation and execution
- Media Training
Finance
- Business Development Services
- Funding Advise (Seed through to Pre IPO)
- Investor Relations
- Capital introduction
- Tax and Accountancy
Ethics
- Social Media Implementation and Strategy
- Public Relations and Press Liaison
- Website Development, Search Engine Optimisation and UI/UX Strategies
- Event organisation and execution
Animations
As part of our mission, we support charities and other value-aligned actors in the psychedelic space to consolidate and develop their impact. Although much of this support is ‘behind-the-scenes’, some of our most enjoyable work involves creating bespoke animations to visually summarise an idea, platform or project.
Reports
We produce reports that clarify complex questions and open up pathways for more informed engagement with psychedelics. These publications are designed to support patients, practitioners, policymakers and advocates in navigating evolving legal, medical and cultural landscapes.
Some of our most meaningful contributions come through these public reports. Together, they provide resources that strengthen the case for safe, evidence-based access to psychedelics.
News
Our acheivements are most consistently found on the Drug Science blog. There, we contribute articles that explore our contributions to issues such as access to psilocybin treatment, evolving drug policy, and the lived experiences of patients and practitioners.
Germany Pioneers Compassionate Psilocybin Access for Treatment-Resistant Depression in EU First
UK Government supports ACMD plan to enable research with schedule 1 medicines such as psilocybin and MDMA
Innovating through tradition: kava-talanoa as a culturally aligned medico-behavioral therapeutic approach to amelioration of PTSD symptoms
Drug Science and University College London Collaboration: Advancing MDMA-Assisted Therapy
Drug Science Podcast
Psilonautica created and continues to produce the Drug Science Podcast, the UK’s leading drugs podcast.
Guests from Michael Pollan to James Fadiman and everyone in between have joined Prof David Nutt and the Drug Science team in conversation.